Important Safety Information
Prescribing Information
Patient Support
Visit Our Patient Site
View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Collapse Important Safety Information
Expand Important Safety Information

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Prescribing Information DownloadPatient Websites HCP Websites menu

Visit Patient Site

Sucraid® (sacrosidase) Oral Solution

The only FDA-approved enzyme replacement therapy indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

HOW TO ORDER
HOW TO ORDER
View Important Safety Information

IMPORTANT SAFETY INFORMATION:

Sucraid® (sacrosidase) Oral Solution

The only FDA-approved enzyme replacement therapy indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.

Sucraid® (sacrosidase) Oral Solution

The only FDA-approved enzyme replacement therapy indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.
About CSID

About CSID

Congenital Sucrase-Isomaltase Deficiency (CSID) also known as Genetic Sucrase-Isomaltase Deficiency (GSID).

How to Diagnose CSID

The clinical diagnosis of CSID can be challenging. Here are available objective tests that can aid in your diagnosis.

About Sucraid

About Sucraid®

Sucraid® is the only FDA-approved enzyme replacement therapy indicated for the treatment of CSID.

How to Order

Information on ordering Sucraid® and programs to make Sucraid® affordable for all patients.

What is Sucraid®?

Sucraid® is an enzyme replacement therapy that contains sacrosidase as a substitute for sucrase, which is one of the enzymes that is defective in individuals who have Congenital Sucrase-Isomaltase Deficiency (CSID).

Sacrosidase facilitates the breakdown of sucrose (sugar) into its constituent monosaccharide units, glucose and fructose, for absorption from the small intestine. Sucraid® has been documented to help relieve the gastrointestinal symptoms associated with CSID, and as a result, help affected individuals consume a more normal diet that includes sucrose-containing foods.

 
How Sucraid® Works video

See how Sucraid® works. Watch the Video

Proper dosing is essential for Sucraid® to be effective.

The proper Sucraid® dose depends on the patient’s body weight. The dose for patients weighing 33 lb or less is 1 mL, and is 2 mL for patients weighing more than 33 lb. Sucraid® is available in 118 mL (4 fluid oz) bottles or 2 mL single-use containers. Each single-use container holds one dose for patients over 33 lb and up to 2 doses for patients weighing 33 lb and less.

The appropriate dose of Sucraid® is to be taken orally with each meal or snack, diluted with 4 ounces (120 mL) of water, milk, or infant formula. Please refer to the Prescribing Information and Instructions for Use for full dosing instructions. Because heat or acidity may decrease the potency of Sucraid®, the diluting liquid should not be a warmed or acidic liquid such as fruit juice. It is recommended that approximately half the dose be taken at the beginning of a meal or snack, and the remainder taken during a meal or snack.

Information about CSID and Sucraid®

Sucraid® Single Use Container
About CSID

Congenital Sucrase-Isomaltase Deficiency (CSID), also known as Genetic Sucrase-Isomaltase Deficiency (GSID), is an autosomal recessive disorder that causes a deficiency in sucrase-isomaltase (SI), the enzyme responsible for the metabolism of sucrose and other sugars found in starch, and the subsequent absorption of their metabolites, glucose and fructose.

How to Diagnose CSID

The clinical diagnosis of CSID can be challenging. Here are available objective tests that can aid in your diagnosis.

About Sucraid®

Sucraid® is the only FDA-approved enzyme replacement therapy that is a substitute for sucrase, the digestive enzyme that is missing or not working in patients with genetic sucrase deficiency, a major component of Congenital Sucrase-Isomaltase Deficiency (CSID). Sucraid® facilitates the metabolism of sucrose into its constituent monosaccharide units, glucose and fructose, for absorption from the small intestine. Sucraid® is dispensed in 118-mL translucent plastic bottles, packaged with two bottles per box or 2-mL single-use containers packaged in a foil pouch. Each foil pouch includes five Sucraid® single-use containers. Sucraid® should be taken with each meal or snack, dissolved in 4 ounces of water, milk, or infant formula.

See Important Safety Information below.

How to Order Sucraid®

Click the How to Order tab above to download a Sucraid® Prescription Form or call the specialty pharmacy at 1-833-800-0122. Sucraid® is only available through an exclusive specialty pharmacy provider that ships the therapy directly to the patient’s home or physician’s office.

Patient Support

The SucraidASSIST™ program provides patients with access to a variety of support services, including insurance assessment, financial assistance for all Sucraid® patients, pharmacy services, peer support coaching, and nutrition counseling.

Watch Now

Could It Be CSID? with William D. Chey, MD

Join William D. Chey, MD as he reveals recent data that suggest how CSID may be an overlooked cause of unresolved GI symptoms in adults previously diagnosed with and treated for IBS-D.

Download Templates

for Letters of Medical Necessity

Biopsy

Genetic Test

History

Activity

RX Trial

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Do not prescribe Sucraid® to patients known to be hypersensitive to yeast, yeast products, papain, or glycerin (glycerol).
  • Sucraid® may cause a serious allergic reaction. Patients should stop taking Sucraid® and get emergency help immediately if any of the following side effects occur: difficulty breathing, wheezing, or swelling of the face. Care should be taken when administering initial doses of Sucraid® to observe any signs of acute hypersensitivity reaction.
  • Although Sucraid® provides replacement therapy for the deficient sucrase, it does not provide specific replacement therapy for the deficient isomaltase.
  • Adverse reactions as a result of taking Sucraid® may include worse abdominal pain, vomiting, nausea, diarrhea, constipation, difficulty sleeping, headache, nervousness, and dehydration.
  • Before prescribing Sucraid® to diabetic patients, the physician should consider that Sucraid® will enable sucrose hydrolysis and the absorption of those hydrolysis products, glucose and fructose.
  • The effects of Sucraid® have not been evaluated in patients with secondary (acquired) disaccharidase deficiency.
  • DO NOT HEAT SOLUTIONS CONTAINING SUCRAID®. Do not put Sucraid® in warm or hot fluids. Do not reconstitute or consume Sucraid® with fruit juice since the acidity of the juice may reduce the enzyme activity of Sucraid®. Half of the reconstituted Sucraid® should be taken at the beginning of the meal or snack and the other half during the meal or snack.
  • Sucraid® should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light; single-use containers can be removed from refrigeration and stored at 59°F-77°F (15°C-25°C) for up to 3 days (72 hours). Refer to Instructions for Use for full information on how to take Sucraid®.

Indication

Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.